07:28 AM EDT, 10/30/2024 (MT Newswires) -- Bausch + Lomb ( BLCO ) on Tuesday reported a lower adjusted profit even as revenue rose.

The company, which specializes in eye health, reported adjusted profit, excluding most one-time items, of US$61 million, or US$0.17 per diluted share, compared with US$76 million, or US$0.22 per share, last year.

Total revenue was 19% higher, to US$1.2 billion. All three B+L segments recorded higher sales, with pharmaceuticals logging the biggest increase of 76% -- from last year's US$174 million, to US$306 million. According to the statement, the company reported "solid performance" in its dry eye portfolio.

Bausch + Lomb ( BLCO ) raised its 2024 revenue guidance to US$4.725 - US$4.825 billion, from US$4.7 billion - US$4.8 billion.

"Our focus on execution continues to drive growth, with significant opportunity ahead," said Brent Saunders, chairman and CEO. "We're in the middle of multi-dimensional launch cycles around the world, covering all our businesses and targeting all our audiences."